News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK)'s Deal With Japan's Chiome Bioscience Aims to Discover New Cancer Drugs



4/12/2012 8:23:48 AM

GlaxoSmithKline (NYSE:GSK) is working with a Japanese biotechnology company to see if that company’s technology can find potential new cancer treatments. GSK’s agreement with Tokyo-based Chiome Bioscience calls for the companies to first conduct a pilot study using Chiome’s proprietary technology. Chiome’s proprietary platform technology can generate antibodies. Under the agreement, GSK and Chiome will generate monoclonal antibodies, antibodies that can seek out and recognize cancers anywhere in the body. Depending on how the pilot goes, GSK has the option to pursue further development. No financial terms were disclosed.

Read at News Release
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES